Loading
Bristol Myers Squibb Co Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 29 Apr 2025.
Bristol Myers Squibb Co: what insiders have been doing
Bristol Myers Squibb Co, founded in 1989, is a Healthcare & Pharma company based in New York City, United States. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 39 filings signed by 16 insiders.
No insider bought on the market over the period, while 1 insider filed 2 sales totalling €1.6M. At €1.4M, the sale published on 2 April 2026 by Elkins David V is the largest of the period.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 39 filings here. Over the whole record (from 2016), the tally stands at 7 purchases and 44 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 48.19 bn USD and net income at 7.05 bn USD; the dividend was 2.49 USD per share.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
202
Thresholds
n/a
Buy Volume
€1M
7 ops. · all time
Sell Volume
€65M
44 ops. · all time
Who traded when
BuySaleDavid Elkins V3 sales
Hirawat Samit3 buys
Holzer Phil M2 sales
Boerner Christopher S.1 buy
Hickey Benjamin1 sale
Massacesi Cristian1 sale
Analyst consensus: bullish or bearish?
Analysts rate Bristol Myers Squibb Co Buy (bullish), based on 24 analysts. Average price target: US$65.63.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 3,229 of 24,148 companies
71.1
score / 100
Value68
Quality75
FCF yld11%
Earn yld5.8%
EV/EBITDA11.1x
ROE47%
Gross mgn71%
Net mgn15%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$59.28
Analyst consensus
24 analystsBuy
US$41.00Target US$65.63(+11%)US$82.00
Income statement
RevenueUS$48.2B
Gross profitUS$34.3B71% margin
EBITDAUS$15.2B32% margin
Net incomeUS$7.1B18.9% margin
Valuation
PER (trailing)12.5x
PER (forward)8.9x
P/Book5.4x
Beta0.18
Balance sheet & cash
Market capUS$121.1B
Total debtUS$47.1B
Free Cash FlowUS$12.8B
Debt / Equity202%
Profitability & ownership
ROE46.6%
ROA10.7%
% insiders0.1%
% institutions84.9%
Last declaration on 5 October 2026
Declarations202 total
4,559 shares0Common Stock, $0.10 par valueSEC:0001995058-26-000007:0
2,332 shares@ US$61.15Common Stock, $0.10 par valueSEC:0001995058-26-000007:1
6,249 shares@ US$64.5718.9% of flowCommonSEC144:0001959173-26-006809
1,236 shares@ US$66.9224.5% of flowCommon Stock, $0.10 par valueSEC:0002070839-26-000007:0
633 shares@ US$66.9212.6% of flowCommon Stock, $0.10 par valueSEC:0002070839-26-000007:1
500 shares@ US$67.5044.7% of flowCommonSEC144:0001959173-26-006424
1,061 shares0Common Stock, $0.10 par valueSEC:0001995058-26-000005:0
51,172 shares0Common Stock, $0.10 par valueSEC:0002080176-26-000004:0
26,175 shares@ US$65.3181.1% of flowCommon Stock, $0.10 par valueSEC:0002080176-26-000004:1
543 shares@ US$65.31100.0% of flowCommon Stock, $0.10 par valueSEC:0001995058-26-000005:1
20,460 sharesCommon Stock, $0.10 par valueSEC:0001656082-26-000004:0
8,040 shares0Common Stock, $0.10 par valueSEC:0002070839-26-000005:0
3,876 shares@ US$54.7262.9% of flowCommon Stock, $0.10 par valueSEC:0002070839-26-000005:1
599 shares@ US$58.22100.0% of flowCommon Stock, $0.10 par valueSEC:0001975719-26-000004:2
1,373 shares0Common Stock, $0.10 par valueSEC:0001975719-26-000004:0
203 shares0Common Stock, $0.10 par valueSEC:0001975719-26-000004:1
3,307 shares0Common Stock, $0.10 par valueSEC:0001917325-26-000004:0
25,519 shares@ US$61.6015.7% of flowCommon Stock, $0.10 par valueSEC:0001451604-26-000004:0
4,481 shares@ US$62.052.8% of flowCommon Stock, $0.10 par valueSEC:0001451604-26-000004:1
1,692 shares@ US$61.73100.0% of flowCommon Stock, $0.10 par valueSEC:0001917325-26-000004:1
811 shares0Common Stock, $0.10 par valueSEC:0002005210-26-000002:0
912 shares0Common Stock, $0.10 par valueSEC:0001995058-26-000003:0
1,828 shares0Common Stock, $0.10 par valueSEC:0001975719-26-000002:0
1,107 shares0Common Stock, $0.10 par valueSEC:0001773367-26-000002:0
639 shares0Common Stock, $0.10 par valueSEC:0002070839-26-000002:0
25 of 202 declarations
About Bristol Myers Squibb Co
Bristol Myers Squibb Co. (NYSE: BMY) is a major U.S.-based biopharmaceutical company headquartered in Princeton, New Jersey, United States. Its roots date back to 1887, when William Bristol and John Myers acquired Clinton Pharmaceutical Company; over time, the business evolved through major corporate combinations, including the Squibb heritage, into one of the best-known names in global pharmaceuticals. For international investors, BMS stands out as a company that combines large, cash-generative legacy franchises with an innovation-led pipeline focused on serious diseases. ([bms.com](https://www.bms.com/about-us/our-company/history-timeline.html?utm_source=openai))
The company discovers, develops, manufactures and commercializes therapies across several important therapeutic areas, with particular strength in oncology, hematology, immunology, and cardiovascular disease. Its core portfolio includes blockbuster and specialist brands such as Opdivo, Eliquis, Revlimid, Camzyos, Breyanzi, Reblozyl, Opdualag, Yervoy, Orencia, Sotyktu and Zeposia. That mix is important from an equity-analysis perspective because it combines mature assets that still produce substantial revenue with newer products designed to offset patent expiries and generic erosion. ([bms.com](https://www.bms.com/media/media-library/key-facts.html?utm_source=openai))
Read moreShow less
Competitively, Bristol Myers Squibb ranks among the leading global innovative pharma companies. It competes with large multinational peers across different therapeutic segments, but it has especially deep positioning in immuno-oncology and selected cardiovascular treatments. At the same time, the company remains exposed to generic competition on older products, which makes the strength of its pipeline, clinical execution and business-development strategy central to the investment case. In its 2025 full-year results, BMS reported revenue of $48.2 billion and guided to 2026 revenue of approximately $46.0 billion to $47.5 billion, underscoring the scale of the business while also reflecting ongoing portfolio transition dynamics. ([bms.com](https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_financials/quarterly_reports/2025/BMY-Q4-2025-Earnings-Press-Release.pdf))
BMS has a broad global footprint, with sales in the United States and international markets, and a worldwide network of research, development and commercial operations. Recent headlines highlight an active pipeline and continued strategic investment: in February 2026, the FDA accepted the NDA for iberdomide in relapsed/refractory multiple myeloma; in May 2026, BMS announced a strategic collaboration with Hengrui Pharma covering 13 early-stage programs in oncology, hematology and immunology; and during the first half of 2026 the company reported positive Camzyos data as well as expanded Opdivo approvals in classical Hodgkin lymphoma. For equity investors, these developments reinforce BMS’s thesis as a diversified large-cap biopharma company whose medium-term upside depends on successful launches, label expansion and pipeline conversion. ([investors.bms.com](https://investors.bms.com/iframes/press-releases/press-release-details/2026/U-S--Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Iberdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
